<?xml version="1.0" encoding="UTF-8"?>
<p>The use of antiretroviral therapy (ART) has shown markedly decreased sickness and death rates in persons living with HIV (PLWH) (
 <xref rid="R1" ref-type="bibr">
  <italic>1</italic>
 </xref>
 <italic>–</italic>
 <xref rid="R3" ref-type="bibr">
  <italic>3</italic>
 </xref>). Meanwhile, the emergence of antimicrobial drug resistance in HIV-1 is raising public health concerns (
 <xref rid="R4" ref-type="bibr">
  <italic>4</italic>
 </xref>,
 <xref rid="R5" ref-type="bibr">
  <italic>5</italic>
 </xref>). Nationwide estimates of the prevalence of drug resistance mutations (DRMs) are not available in Germany (
 <xref rid="R6" ref-type="bibr">
  <italic>6</italic>
 </xref>); the reported prevalence of transmitted HIV-1 DRMs differ across regions and risk groups from 10.4%–17.2%, as described in 2 cohort studies from the German ClinSurv-HIV cohort and the Cologne-Bonn cohort (
 <xref rid="R6" ref-type="bibr">
  <italic>6</italic>
 </xref>,
 <xref rid="R7" ref-type="bibr">
  <italic>7</italic>
 </xref>).
</p>
